secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001171843-25-005815
Event type: litigation
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus wins claim construction ruling in patent suit vs Pfizer/BioNTech over COVID-19 vaccine LNP technology
--------------------------------------------------------------------------------

- Court adopted Arbutus's proposed construction for 'fully encapsulated' as 'contained inside' in five LNP patents.
- Court rejected Pfizer/BioNTech's proposal and declined to add 'as distinct from partially' used in prior Moderna ruling.
- Patent claims cover lipid nanoparticle compositions used in COMIRNATY COVID-19 vaccine; damages sought.
- Ruling narrows scope of disputed terms, strengthening Arbutus's infringement case; trial on merits pending.
- Arbutus and licensee Genevant Sciences assert five patents against Pfizer/BioNTech in New Jersey action.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325005815/0001171843-25-005815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325005815/f8k_091025.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer